 Following consultations with the FDA, ChemoCentryx Inc NASDAQ: CCXI filed an amendment to its marketing application seeking approval for avacopan to treat Anti-neutrophil Cytoplasmic Autoantibody ANCA-associated vasculitis addressing concerns raised during the FDA Advisory Committee meeting in May. The FDA has indicated that the filing constitutes a significant amendment to the NDA and will result in the setting of a new PDUFA goal date of October 7. 